Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center, discusses side effects seen with PD-1 and PD-L1 inhibitors as well as the recent USPSTF screening recommendations for breast cancer.
Lee Schwartzberg, MD, FACP, chief of Division of Hematology Oncology and professor of medicine at the University of Tennessee Health Science Center, discusses side effects seen with PD-1 and PD-L1 inhibitors as well as the recent USPSTF screening recommendations for breast cancer.
Transcript (slightly modified)
Have the side effects of new checkpoint inhibitors in breast cancer been manageable in trials?
Yes, both in breast cancer and in other diseases the side effects are generally manageable. When they’ve been compared head-to-head in other diseases, the side effects of PD-1 and PD-L1 inhibitors are generally less in terms of major side effects compared to chemotherapy. But everyone needs to keep in mind that the toxicity profile is different for checkpoint inhibitors; they get autoimmune types of complications as opposed to hymenologic or cytotoxic complications.
What are your thoughts on the recent USPSTF screening recommendations for breast cancer?
Well, I think the recent recommendations are quite restrictive. I think they are certainly evidence-based, but I think they don’t take into account the totality of benefit from screening. So I think that while it’s reasonable to recommend shared decision making for younger women, I think, in general, when you talk to younger women between the ages of 40 and 50, most all of them want to be screened. I’m not sure there’s a lot of benefit in having that discussion. And I think that there’s actually an absence of data in the older women so my feeling is that lack of evidence shouldn’t be interpreted as proof that it doesn’t work there. We need more information in the older women.
Males With Hemophilia A Report Physical, Mental Burdens of Disease Regardless of Severity
April 25th 2024Self-reported data from adult and pediatric males with hemophilia A show that burden of the disease persists regardless of severity, highlighting a need for improved prophylactic treatment.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen